OvaScience to Present at Upcoming Investor Conferences in September
WALTHAM, Mass.–(BUSINESS WIRE)–OvaScienceSM (NASDAQ: OVAS), a global fertility company
focused on the discovery, development and commercialization of new
treatment options, today announced that Harald Stock, Ph.D., President
and Chief Executive Officer, will present a corporate overview at three
upcoming conferences:
• |
Baird 2016 Global Healthcare Conference |
|
Date: Wednesday, September 7, 2016 |
||
Time: 7:55 a.m. ET |
||
Location: New York, NY |
||
• |
Rodman & Renshaw 18th Annual |
|
Date: Monday, September 12, 2016 |
||
Time: 3:25 p.m. ET |
||
Location: New York, NY |
||
• |
Ladenburg Thalmann 2016 Healthcare Conference |
|
Date: Tuesday, September 27, 2016 |
||
Time: 3:30 p.m. ET |
||
Location: New York, NY |
Live webcasts of the presentations can be accessed by visiting the
Investors section of the Company’s website at www.ovascience.com.
A replay of the webcasts will be archived on the OvaScience website for
two weeks following each presentation.
About OvaScience
OvaScienceSM (NASDAQ: OVAS) is a global fertility company
dedicated to improving treatment options for women around the
world. OvaScience is discovering, developing and commercializing new
fertility treatments because we believe women deserve more options.
Each OvaScience treatment is based on the Company’s proprietary
technology platform that leverages the breakthrough discovery of egg
precursor (EggPCSM) cells – immature egg cells found inside
the protective ovarian lining. The AUGMENTSM treatment, a
fertility option specifically designed to improve egg health, is
available in certain IVF clinics in select international
regions. OvaScience has commenced a non-commercial preceptorship
training program with the OvaPrimeSM treatment, which could
increase a woman’s egg reserve, and is developing the OvaTureSM treatment,
a potential next-generation IVF treatment that could help a woman
produce healthy, young, fertilizable eggs without hormone injections.
OvaScience treatments are not available in the U.S. For more
information, please visit www.ovascience.com and
www.augmenttreatment.com and
connect with us on Twitter and Facebook.
###
Contacts
Media and Investor Contact:
OvaScience
Jennifer
Viera, 617-420-8748
jviera@ovascience.com